# Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects

> **NCT06649409** · PHASE1 · COMPLETED · sponsor: **Santhera Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Pharmacodynamic

## Interventions

- **DRUG:** Vamorolone
- **DRUG:** Eplerenone
- **DRUG:** Fludrocortisone

## Key facts

- **NCT ID:** NCT06649409
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-05
- **Primary completion:** 2024-06-29
- **Final completion:** 2024-07-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649409, "Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06649409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*